-
Something wrong with this record ?
Imaging of protein synthesis: in vitro and in vivo evaluation of (44)Sc-DOTA-puromycin
S. Eigner, DR. Vera, M. Fellner, NS. Loktionova, M. Piel, O. Lebeda, F. Rösch, TL. Roß, KE. Henke,
Language English Country United States
Document type Journal Article
NLK
ProQuest Central
from 2005-01-01 to 2019-01-31
Medline Complete (EBSCOhost)
from 2011-02-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 2005-01-01 to 2019-01-31
Health & Medicine (ProQuest)
from 2005-01-01 to 2019-01-31
- MeSH
- Heterocyclic Compounds, 1-Ring chemistry pharmacokinetics pharmacology MeSH
- Kinetics MeSH
- Rats MeSH
- Humans MeSH
- Molecular Imaging methods MeSH
- Cell Line, Tumor MeSH
- Positron-Emission Tomography MeSH
- Proteins analysis chemistry metabolism MeSH
- Protein Biosynthesis MeSH
- Puromycin analogs & derivatives pharmacokinetics pharmacology MeSH
- Scandium chemistry pharmacokinetics MeSH
- Tissue Distribution MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Humans MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
PURPOSE: The purpose of this study was to investigate whether (44)Sc-labeled puromycin can be utilized for imaging of protein synthesis in vivo. METHODS: For micro-positron emission tomographic (μPET) studies, 20-25 MBq of [(44)Sc]-DOTA-puromycin was administered to tumor-bearing rats, and animals were scanned for 1 h dynamically. Results were further validated by dissecting organs and tissues of the animals after the measurement and in vitro blocking experiments using puromycin or cycloheximide to block protein synthesis. RESULTS: μPET images of tumor-bearing rats showed significant tumor uptake of [(44)Sc]-DOTA-puromycin and a clear-cut tumor visualization. In both blocking experiments, cellular uptake of [(44)Sc]-DOTA-puromycin ([(44)Sc]-DOTA-Pur) could be suppressed by blocking protein synthesis. CONCLUSIONS: We report for the first time successful μPET imaging with (44)Sc obtained from a (44)Ti/(44)Sc generator, as well as noninvasive μPET imaging of ribosomal activity, respectively protein synthesis, with a puromycin-based radiopharmaceutical and the direct correlation between cellular uptake of [(44)Sc]-DOTA-Pur and protein synthesis.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14041031
- 003
- CZ-PrNML
- 005
- 20140114102207.0
- 007
- ta
- 008
- 140107s2013 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11307-012-0561-3 $2 doi
- 035 __
- $a (PubMed)22565849
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Eigner, Sebastian
- 245 10
- $a Imaging of protein synthesis: in vitro and in vivo evaluation of (44)Sc-DOTA-puromycin / $c S. Eigner, DR. Vera, M. Fellner, NS. Loktionova, M. Piel, O. Lebeda, F. Rösch, TL. Roß, KE. Henke,
- 520 9_
- $a PURPOSE: The purpose of this study was to investigate whether (44)Sc-labeled puromycin can be utilized for imaging of protein synthesis in vivo. METHODS: For micro-positron emission tomographic (μPET) studies, 20-25 MBq of [(44)Sc]-DOTA-puromycin was administered to tumor-bearing rats, and animals were scanned for 1 h dynamically. Results were further validated by dissecting organs and tissues of the animals after the measurement and in vitro blocking experiments using puromycin or cycloheximide to block protein synthesis. RESULTS: μPET images of tumor-bearing rats showed significant tumor uptake of [(44)Sc]-DOTA-puromycin and a clear-cut tumor visualization. In both blocking experiments, cellular uptake of [(44)Sc]-DOTA-puromycin ([(44)Sc]-DOTA-Pur) could be suppressed by blocking protein synthesis. CONCLUSIONS: We report for the first time successful μPET imaging with (44)Sc obtained from a (44)Ti/(44)Sc generator, as well as noninvasive μPET imaging of ribosomal activity, respectively protein synthesis, with a puromycin-based radiopharmaceutical and the direct correlation between cellular uptake of [(44)Sc]-DOTA-Pur and protein synthesis.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a heterocyklické sloučeniny monocyklické $x chemie $x farmakokinetika $x farmakologie $7 D006573
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a molekulární zobrazování $x metody $7 D057054
- 650 _2
- $a pozitronová emisní tomografie $7 D049268
- 650 _2
- $a proteosyntéza $7 D014176
- 650 _2
- $a proteiny $x analýza $x chemie $x metabolismus $7 D011506
- 650 _2
- $a puromycin $x analogy a deriváty $x farmakokinetika $x farmakologie $7 D011691
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a skandium $x chemie $x farmakokinetika $7 D012538
- 650 _2
- $a tkáňová distribuce $7 D014018
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vera, Denis R Beckford $u -
- 700 1_
- $a Fellner, Marco $u -
- 700 1_
- $a Loktionova, Natalia S $u -
- 700 1_
- $a Piel, Markus $u -
- 700 1_
- $a Lebeda, Ondrej $u -
- 700 1_
- $a Rösch, Frank $u -
- 700 1_
- $a Roß, Tobias L $u -
- 700 1_
- $a Henke, Katerina Eigner $u -
- 773 0_
- $w MED00008643 $t Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging $x 1860-2002 $g Roč. 15, č. 1 (2013), s. 79-86
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22565849 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140107 $b ABA008
- 991 __
- $a 20140114102911 $b ABA008
- 999 __
- $a ok $b bmc $g 1005427 $s 839543
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 15 $c 1 $d 79-86 $i 1860-2002 $m Molecular imaging and biology $n Mol Imaging Biol $x MED00008643
- LZP __
- $a Pubmed-20140107
